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Abstract
This is the first multi- institutional retrospective survey of the long- term outcomes 
of proton therapy (PT) for prostate cancer in Japan. This retrospective analysis 
comprised prostate cancer patients treated with PT at seven centers between 
January 2008 and December 2011 and was approved by each Institutional Review 
Board. The NCCN classification was used. Biochemical relapse was based on 
the Phoenix definition (nadir + 2.0 ng/mL). Toxicities were evaluated with the 
Common Terminology Criteria for Adverse Events version 4.0. There were 215, 
520, and 556 patients in the low- risk, intermediate- risk, and high- risk groups, 
respectively. The median follow- up period of surviving patients was 69 months 
(range: 7–107). Among all patients, 98.8% were treated using a conventional 
fractionation schedule and 1.2% with a hypofractionation schedule; 58.5% and 
21.5% received neoadjuvant and adjuvant androgen deprivation therapy, respec-
tively. The 5- year biochemical relapse- free survival (bRFS) and overall survival 
rates in the low- risk, intermediate- risk, and high- risk groups were 97.0%, 91.1%, 
and 83.1%, and 98.4%, 96.8%, and 95.2%, respectively. In the multivariate 
analysis, the NCCN classification was a significant prognostic factor for bRFS, 
but not overall survival. The incidence rates of grade 2 or more severe late 
gastrointestinal and genitourinary toxicities were 4.1% and 4.0%, retrospectively. 
This retrospective analysis of a multi- institutional survey suggested that PT is 
effective and well- tolerated for prostate cancer. Based on this result, a multi- 
institutional prospective clinical trial (UMIN000025453) on PT for prostate 
cancer has just been initiated in order to define its role in Japan.
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Introduction
Prostate cancer is the second most common cancer in 
men with an annual estimated number of deaths of 300,000 
worldwide [1]. The number of patients with prostate 
cancer has also increased in Japan, and it was estimated 
to be the most common malignant tumor in men in 
2016 [2]. A treatment algorithm based on staging and 
risk classification is used for localized prostate cancer, 
and surgery, radiotherapy, hormone therapy, and a mul-
tidisciplinary treatment combining these modalities are 
mainly performed. In a phase III study in which previous 
surgical treatment and radiotherapy for prostate cancer 
were compared, the outcomes of radiotherapy and total 
prostatectomy for early prostate cancer were found to be 
similar for the local control rate and bRFS [3, 4]. Prostate 
cancer is one of the diseases treated with charged- particle 
radiation therapy, such as proton and heavy- ion beams, 
in many patients because treatment outcomes were 
improved by enhancing dose distributions based on expe-
rience with X- ray radiation therapy and dose escalations 
on the assumption of this Ref. [5, 6], and high- dose 
concentrations of charged- particle beams were considered 
to be useful [7]. In addition, the exposure dose of proton 
therapy (PT) is lower in the rectum and urinary bladder 
around the prostate than that of X- ray irradiation applied 
at a similar dose [8, 9], for which reductions in adverse 
events may be expected. In a study by Loma Linda 
University, local PT at a total dose of 74 Gy equivalent 
(GyE) in 37 fractions was applied to 911 patients between 
1991 and 1997; the 5- year relapse- free survival rate was 
82%, and the incidence rates of grade 2 gastrointestinal 
(GI) and genitourinary (GU) toxicities were 3.5 and 5.4%, 
respectively, which were more favorable than the outcomes 
of X- ray radiation therapy at that time [7, 10]. In Japan, 
local PT was applied to 151 patients between 2004 and 
2007 in a multicenter study involving three institutions, 
and the incidence rates of grade 2 GI and GU toxicities 
were 2.0 and 4.1%, respectively, showing a favorable out-
come [11].
On the other hand, intensity- modulated radiation ther-
apy (IMRT) with external X- ray irradiation has been widely 
performed. In physical studies, the irradiated volumes of 
the rectum and urinary bladder were smaller with PT 
[12, 13]; however, differences in toxicities and quality of 
life (QOL) between PT and IMRT currently remain unclear. 
Sheets et al. [14] reported no significant differences in 
toxicities or QOL evaluations between PT and IMRT. 
Hoppe et al. [15] found significant differences in rectal 
urgency and frequent bowel movements, but not in other 
QOL scores between these two groups. Judgments and 
comparisons of the usefulness of IMRT are recommended 
for the application of PT to the treatment of prostate 
cancer, and the collection of evidence by prospective reg-
istration is considered desirable in the PT model policies 
issued by American Society for Radiation Oncology [16], 
indicating that the efficacy of PT remains controversial. 
In a systematic review, PT was not found to be cost- 
effective for prostate cancer [17]. In this study, the long- 
term outcomes of patients who received PT at all seven 
institutions in Japan after 2008 were surveyed, with the 
aim of developing a new treatment strategy for the future.
Materials and Methods
Study design and patient eligibility
This was a retrospective analysis on prostate cancer treated 
with PT between January 2008 and December 2011 
based on each institution’s protocol decided by each 
Institutional Review Board (IRB) and was approved as a 
survey of the Japanese Radiation Oncology Study Group 
(JROSG2016-R12). Seven centers in Japan were applicable 
during the surveyed period in this study, and this analysis 
was newly approved by each IRB. The host IRB number 
was 16- 04- 543- 24. Inclusion criteria were as follows: (1) 
histologically confirmed primary prostate cancer; (2) no 
lymph node and distant metastasis using computed tomog-
raphy (CT) scans and bone scans; (3) Japanese men; (4) 
no prior pelvic radiotherapy; (5) hormone- sensitive or 
hormone- naive prostate cancer; (6) minimum follow- up 
of 6 months for surviving patients; and (7) written informed 
consent. The NCCN classification was used for the risk 
categorization of prostate cancer. However, the very- high- 
risk group according to the NCCN criteria was included 
in the high- risk group. Biochemical relapse was based on 
the Phoenix definition (nadir + 2.0 ng/mL). After PT, 
patients were followed up by regular studies including 
physical examinations and tumor marker evaluations. 
Prostate magnetic resonance imaging (MRI), pelvic CT 
scans, and bone scans were typically performed to evaluate 
distant metastases as well as the local tumor status, par-
ticularly when biochemical relapse was suspected or when-
ever necessary. The primary endpoint of this study was 
the 5- year biochemical relapse- free survival (bRFS). The 
secondary endpoints included the following: (1) 5- year 
overall survival (OS); (2) 5- year cause- specific survival 
(CSS); (3) 5- year bRF rates; (4) 5- year clinical relapse- free 
(cRF) rates; and (5) the incidence of grade 2 or more 
severe late GI and GU toxicities. bRFS was defined as 
the interval from the date of the final PT to the last 
follow- up, biochemical relapse, or death date. OS was 
defined as the interval from the date of the final PT to 
the last follow- up or death date. CSS was defined as the 
interval from the date of the final PT to the last follow-
 up or death date relating to prostate cancer. BRF was 
679© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
Proton Therapy for Prostate CancerH. Iwata et al.
defined as the interval from the date of the final PT to 
the last follow- up, biochemical relapse, or clinical relapse. 
CRF was defined as the interval from the date of the 
final PT to the last follow- up or clinical relapse. Predictive 
factors for bRFS, OS, and grade 2 or more severe late 
GI and GU toxicities were also evaluated using statistical 
analyses.
Participating institutions
Seven institutions were equipped to provide PT during 
the periods of this study in Japan (National Cancer Center 
Hospital East, Kashiwa, Chiba; Shizuoka Cancer Center, 
Nagaizumi, Shizuoka; Hyogo Ion Beam Medical Center, 
Tatsuno, Hyogo; University of Tsukuba Faculty of 
Medicine, Tsukuba, Ibaraki; Southern TOHOKU Proton 
Therapy Center, Koriyama, Fukushima; Fukui Prefectural 
Hospital, Fukui, Fukui; and Medipolis Proton Therapy 
and Research Center, Ibusuki, Kagoshima).
Treatment protocols and treatment systems
Proton therapy was delivered at a total dose of 70–80 GyE 
in 35–40 fractions (2 GyE/day, conventional fractionation) 
or 63–66 GyE in 21–22 fractions (3 GyE/day, hypofrac-
tionation). All irradiation doses were calculated at the 
center of the target volume. The accelerator complex 
consisted of a synchrotron (Mitsubishi Electric Corpora-
tion, Kobe, Japan, and Hitachi, Ltd., Tokyo, Japan) or a 
cyclotron (Sumitomo Heavy Industries, Ltd., Tokyo, Japan). 
Patients were treated with 210–235 MeV proton beams. 
Beam ranges were adjusted by a fine degrader. The spread- 
out Bragg peaks (SOBP) of the proton were produced 
using bar- ridge filters. Patient setup was performed daily 
by subtraction of the two sets of orthogonal digital radio-
graphs or in- room CT before each treatment. The transla-
tion and rotation of the patient detected by the positioning 
system were compensated for by adjustments to the treat-
ment couch. The setup was continued until the bony 
landmarks and/or fiducial markers on digitally recon-
structed radiographs agreed within 2 mm. Relative bio-
logical effectiveness (RBE) values for PT were set as 1.1. 
As all tissues are assumed to have almost the same RBE 
for PT, doses expressed in GyE were directly comparable 
to photon doses.
Treatment planning
Radiation treatment plans were performed using a CT- 
based three- dimensional treatment planning system 
(FOCUS- M, CMS, St. Louis, MO, Mitsubishi Electric 
Corporation, Kobe, Japan, and VQA, Hitachi, Ltd., Tokyo, 
Japan). Each patient was immobilized with a custom- made 
thermoplastic cast, and 2- to 3- mm- thick CT images were 
taken under proper defecation and urination control. The 
clinical target volume (CTV) was defined as the prostate 
alone for low- risk patients and as the prostate plus the 
proximal or whole seminal vesicles for intermediate- risk 
and high- risk patients. The planning target volume (PTV) 
consisted of the clinical target volume with optimal mar-
gins to account for uncertainties from the patient setup 
or internal organ motion, which were estimated at each 
institution (5–10 mm). Dose constraints for normal tis-
sues were set on each institution’s provision, which were 
based on the findings of a previous analysis [8]. Bilateral 
opposed fields were used for proton dose delivery. A 
desirable treatment plan was defined as one that covered 
the PTV with 90% or more of the prescribed dose with 
or without the shrinking field technique. Therefore, treat-
ment planning to encompass 95% of the CTV with 95% 
or more of the prescribed dose was sought. Doses were 
calculated based on the pencil beam algorithm. Adequate 
beam parameters, including beam energy, SOBP width, 
and degrader thickness, were assessed with FOCUS- M or 
VQA, taking range uncertainty derived from PT into 
consideration.
Statistical analysis
In comparison with the baseline clinical characteristics of 
the subgroups, Student’s t- test or Wilcoxon’s rank- sum 
test was used for continuous variables, and Fisher’s exact 
test was used for categorical variables. bRFS, OS, CSS, 
and bRF rates were calculated using the Kaplan–Meier 
method. Differences between survival curves were examined 
by the log- rank test. Hazard ratios and 95% confidence 
intervals (CIs) for bRFS, OS, and grade 2 or more severe 
late GI and GU toxicities were estimated using univariate 
and multivariate Cox’s proportional hazards models. In 
the multivariate analysis, clinically meaningful covariates 
were selected from the candidates to avoid the multicol-
linearity of variables. A Fine–Gray competing risk analysis 
was also analyzed for OS. Missing data were excluded 
from the analysis, and the number is also listed in Table 1. 
Values of P < 0.05 were considered to be significant. All 
analyses were performed using SAS software version 9.4 
(SAS Institute, Cary, NC). Toxicities were evaluated with 
the Common Terminology Criteria for Adverse Events 
version 4.0.
Results
Patient and treatment characteristics
The total number of prostate cancer patients in all insti-
tutions during this period was 1,302, and 11 patients 
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were excluded based on the above criteria: Six became 
unable to be followed up within 6 months, one received 
PT as re- irradiation, two had bone metastasis from the 
beginning, and two were foreigners. Therefore, 1291 patients 
were analyzed in this study. Patient characteristics are 
summarized in Table 1. The PT protocol involving 
Table 1. Patient characteristics sorted by the NCCN risk classification.
Variable Level Low Intermediate High P Total
Number N 215 520 556 1291
Age Mean ± SD 65 ± 7 67 ± 7 69 ± 7 <0.001 68 ± 7
Median [Q1, Q3]a 65 [60, 71] 65 [60, 71] 65 [60, 71] <0.001 68 [62, 73]
Performance status 0 208 (96.7)b 489 (94.0) 497 (89.4) <0.001 1194 (92.5)
1+ 7 (3.3) 31 (6.0) 59 (10.6) 97 (7.5)
Operability Operable 201 (93.5) 471 (90.6) 372 (66.9) <0.001 1043 (80.8)
Inoperable 14 (6.5) 49 (9.4) 185 (33.1) 248 (19.2)
T stage 1c- 2a 215 (100) 378 (72.7) 233 (42.1) <0.001 826 (64.1)
2b- 2c 0 (0) 142 (27.3) 125 (22.6) 267 (20.7)
3a- 4 0 (0) 0 (0) 196 (35.3) 196 (15.2)
Unknown 0 0 2 (- ) 2 (- )
PSA value Mean ± SD 6.1 ± 1.6 9.1 ± 4.1 24.5 ± 37.7 <0.001 15.3 ± 26.2
Median [Q1,Q3] 6.0 [5.0, 7.1] 8.0 [5.7, 11.6] 13.4 [7.5, 26.5] <0.001 8.5 [5.8, 14.8]
<10 215 (100) 319 (61.6) 229 (41.2) <0.001 763 (59.2)
10–20 0 (0) 199 (38.4) 112 (20.1) 311 (24.1)
20< 0 (0) 0 (0) 215 (38.7) 215 (16.7)
Unknown 0 2 (- ) 0 2 (- )
Gleason score Mean ± SD 6.0 ± 0.0 6.8 ± 0.4 8.0 ± 0.9 <0.001 7.2 ± 1.0
Median [Q1,Q3] 6 [6, 6] 7 [7, 7] 8 [7, 9] <0.001 7 [6, 8]
6 215 (100) 112 (21.5) 28 (5.1) <0.001 355 (27.6)
7 0 (0) 408 (78.5) 119 (21.5) 527 (40.9)
8–10 0 (0) 0 (0) 406 (73.4) 406 (31.5)
Unknown 0 0 3 (- ) 3 (- )
ADT No 180 (83.7) 276 (53.1) 67 (12.0) <0.001 523 (40.5)
Yes 35 (16.3) 244 (46.9) 489 (88.0) 768 (59.5)
ADT (pattern) None 180 (83.7) 276 (53.1) 67 (12.0) <0.001 523 (40.5)
Neoadjuvant 28 (13.0) 188 (36.2) 275 (49.5) 491 (38.0)
Adjuvant 2 (0.9) 2 (1) 9 (1.6) 13 (1.0)
Neo + adjuvant 5 (2.4) 54 (10) 205 (36.9) 264 (20.5)
ADT period (only yes, 
month)
Mean ± SD 14 ± 17 13 ± 16 19 ± 19 <0.001 17 ± 18
Median [Q1,Q3] 6 [4, 12] 6 [4, 14] 9 [6, 30] <0.001 8 [6, 24]
ADT period (pattern 1, 
month)
0 180 (84.1) 276 (55.5) 67 (12.9) <0.001 523 (42.6)
0<, ≤ 6 19 (8.9) 119 (24.0) 176 (34.0) 314 (25.5)
6<, <12 6 (2.8) 37 (7.4) 65 (12.5) 108 (8.8)
12≤ 9 (4.2) 65 (13.1) 210 (40.6) 284 (23.1)
ADT period 2 (pattern 
2, month)
0 180 (84.1) 276 (55.5) 67 (12.9) <0.001 523 (42.6)
0<, ≤ 12 26 (12.2) 161 (32.4) 249 (48.1) 436 (35.5)
12<, <24 2 (0.9) 27 (5.5) 59 (11.4) 88 (7.2)
24≤ 6 (2.8) 33 (6.6) 143 (27.6) 182 (14.8)
Unknown 1 (- ) 23 (-) 38 (- ) 62 (- )
Diabetes mellitus No 201 (93.5) 468 (90.0) 487 (87.6) <0.001 1156 (89.5)
Yes 14 (6.5) 52 (10.0) 69 (12.4) 135 (10.5)
Hypertension No 173 (80.5) 378 (72.7) 422 (75.9) <0.001 973 (75.4)
Yes 42 (19.5) 142 (27.3) 134 (24.1) 318 (24.6)
Anticoagulant therapy No 195 (90.1) 464 (91.0) 479 (86.2) <0.001 1138 (88.1)
Yes 20 (9.9) 56 (9.0) 77 (13.8) 153 (11.9)
Total dose (GyE)c Mean ± SD 74 ± 1 74 ± 1 75 ± 2 <0.001 75 ± 1
Median [Q1,Q3] 74 [74, 74] 74 [74, 74] 74 [74, 78] <0.001 74 [74, 74]
Higher or lower dosec ≤74 GyE 208 (96.7) 493 (94.8) 405 (72.8) <0.001 1106 (85.7)
74 GyE < 7 (3.3) 27 (5.2) 151 (27.2) 185 (14.3)
NCCN, National Comprehensive Cancer Network; SD, standard deviation; PSA, prostate- specific antigen; ADT, androgen deviation therapy. 
aFirst and third quartiles. bpercent. cThe dose of hypofractionation was converted to conventional dose fractionation using a linear–quadratic model. 
P values were calculated by Student’s t- test or Wilcoxon’s rank- sum test for continuous variables and Fisher’s exact test for categorical variables.
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70–80 GyE in 37–40 fractions (conventional fractionation, 
median; 74 GyE/37 Fr) and that involving 63–66 GyE in 
20–21 fractions (hypofractionation) were delivered to 1274 
(98.8%) and 17 (1.2%) patients, respectively. In total, 
58.5% and 21.5% of patients received neoadjuvant (median, 
6 months; range, 1–140 months) and adjuvant (median, 
24 months; range, 1–90 months) ADT, respectively. More 
than 50% of intermediate- risk patients and approximately 
10% of high- risk patients were not treated with ADT, 
while approximately 30% of intermediate- risk patients and 
more than 50% of high- risk patients received ADT for 
<1 year.
Disease control and survival
The median follow- up period of surviving patients was 
69 months (range: 7–107). Figure 1 shows bRFS according 
to the NCCN classification. Five- year bRFS rates in the 
low- risk, intermediate- risk, and high- risk groups were 
97.0% (95% CI; 93.4–98.6%), 91.0% (88.2–93.2%), and 
83.1% (79.8–86.1%), respectively. Significant differences 
were observed in treatment results among the three groups. 
Figure 2 (A- D) shows OS, CSS, bRF, and cRF according 
to the NCCC group, and a summary of disease control 
and survival rates is provided in Table 2. Biochemical 
relapse was observed in 137 patients, 35 of whom showed 
clinical relapse. Local recurrence was noted in nine patients. 
Twelve patients developed lymph node metastases. In 
addition, 17 patients developed distant bone or lung 
metastases. Fifty- seven patients died, and 53 of them died 
of other diseases.
Table 3 summarizes the results of univariate analyses 
on various factors associated with bRFS and OS. The 
NCCN classification, age, performance status, operability, 
T stage, Gleason score, PSA value, and ADT were associ-
ated with bRFS in the univariate analysis. A multivariate 
analysis was performed using clinical factors selected by 
the univariate analysis (Table 3) with a P value of <0.05 
for each outcome (i.e., bRFS and OS). More important 
factors in this study were selected to avoid the multicol-
linearity of variables in the multivariate analysis. The T 
stage, PSA, and Gleason score were excluded from the 
multivariate analysis because NCCN risk groups were 
categorized based on these factors. In addition, the ADT 
period was excluded from the multivariate model because 
it strongly correlated with the use of ADT. According to 
the multivariate analysis, the NCCN classification was a 
significant prognostic factor for bRFS, but not for OS 
(Table 4). In addition, we were unable to apply the Fine–
Gray competing risk model to this dataset because there 
were only four deaths from prostate cancer.
Complications
The incidence rates of grade 2 or more severe late GI 
and GU toxicities were 4.1% (3.1–5.3%) and 4.0% 
Figure 1. Biochemical relapse- free survival according to the NCCN classification. Significant differences were observed in treatment results among the 
three groups (red line, low risk; pink line, intermediate risk; blue line, high risk).
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(3.1–5.3%), respectively. Grade 3 GI and GU toxicities 
were only observed in six (0.5%) and four (0.3%) patients, 
respectively. Figure 3 shows the cumulative incidence rates 
of grade 2 or more severe GI and GU toxicities curves. 
Table 5 summarizes the results of univariate analyses on 
various factors associated with grade 2 or more severe 
late GI and GU toxicities. According to the univariate 
analysis for GU, significant differences were observed for 
age, operability, PSA, ADT, and dose escalations, whereas 
no significant differences were noted in the multivariate 
analysis.
Discussion
The present study is the first retrospective analysis on a 
multi- institutional survey in Japan to evaluate the effec-
tiveness and feasibility of PT on prostate cancer. In an 
analysis of 1291 patients during a median follow- up period 
greater than 5 years, 5- year bRFS rates were 97.0, 91.1, 
and 83.1% in the low- risk, intermediate- risk, and high- 
risk groups, respectively, and 5- year OS rates were 98.4, 
96.8, and 95.2%, respectively. The incidence of grade 2 
or more severe adverse events was lower than 5% in all 
groups. These results were consistent with previous find-
ings reported by Bryant et al. [18]. Although the present 
study had the limitation of being a retrospective survey, 
such that it was impossible to ascertain details of the 
dose–volume histogram in each case, only a few large- 
scale studies on PT for prostate cancer obtaining long- term 
outcomes have been performed, and this was the initial 
survey in Japan. Therefore, the present results may provide 
important information for the future development of PT.
We investigated whether the NCCN risk classification 
is an independent prognostic factor for bRFS and OS. 
As shown in Tables 3 and 4, it was a prognostic factor 
for bRFS, whereas verification for OS was not possible. 
Figure 2. Overall survival (A), cause- specific survival (B), biochemical relapse- free (C), and clinical relapse- free curves (D) according to the NCCC group 
(red line, low risk; pink line, intermediate risk; blue line, high risk).
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Univariate and multivariate analyses revealed several 
factors associated with bRFS and OS other than the 
NCCN risk groups, that is, age, operability, and per-
formance status. However, only PS was commonly sig-
nificant for bRFS and OS, and this may have been due 
to the influence of a small number of deaths from 
prostate cancer (four patients) despite 40% of all patients 
being included in the high- risk group. The total dose 
showed no significant difference for all endpoints when 
analyzed with a continuous variable or in a dichotomous 
group. However, the risk seemed to decrease as the 
dose increased.
Although a combination with ADT is a well- known 
prognostic factor associated with biochemical relapse 
[19–21], the irradiation dose was approximately 70 Gy 
in these studies; the contribution of high- dose irradiation 
to bRFS and OS currently remains unknown. In the 
present study, as irradiation was applied at 70–80 Gy 
(median: 74 GyE delivered in 37 fractions) including the 
high- risk group, the contribution of ADT to bRFS and 
OS was unclear in the multivariate analysis. Even when 
only the intermediate- risk or high- risk group was included 
in the analysis, the CI of the hazard ratio was wide due 
to the small number of events and ADT performed in 
most patients, which is inappropriate for statistical analy-
ses. Thus, a retrospective analysis of the additional effects 
of ADT for PT and optimum combination periods was 
difficult in the present study.
Patients at very high risk were analyzed as those at 
high risk, and this was another limitation of the present 
study. This was due to insufficient information on the 
positive core number. However, the overall 5- year bRFS 
rate was 83.1% in the high- risk group including 
very- high- risk patients, whereas that of patients treated 
with neoadjuvant + adjuvant long- term ADT was 37%, 
suggesting that the outcome was favorable. As the median 
follow- up period was only 69 months, longer course 
observations may be necessary for the final evaluation of 
OS from prostate cancer.
In the past two decades, IMRT for localized prostate 
cancer has been spreading worldwide. Favorable outcomes 
with IMRT for prostate cancer have accumulated, and 
IMRT with or without ADT is becoming an indispensable 
treatment modality for patients who refuse surgery or are 
medically inoperable. An alternative to or theoretically 
better treatment option than IMRT is PT, and a com-
parison among these treatment modalities needs to be 
performed for physical dose distributions and biological 
effectiveness [22, 23]. Previous planning studies comparing 
PT and IMRT suggested the benefits of reducing the dos-
age of the surrounding OARs of PT over IMRT within 
the low- to medium- dose range of radiation rather than 
the high- dose range [12]. In the present study, the inci-
dence rates of grade 2 or more severe adverse events of 
the GI and GU were lower than 5%. Representative results 
for IMRT and PT for prostate carcinoma are shown in 
Table 6 [10, 18, 24–28]. The passive method and bone 
reconstruction were employed for the irradiation method 
in PT in all and more than 90% of cases, respectively. 
The internal prostate motion was 4–7 mm, being non- 
negligible, as reported by Bylund [29] and Frank et al. 
[30]. The setup error of internal motion may be canceled 
by marker verification, which reduces the lateral margins 
of the rectum and urinary bladder. Furthermore, rectal 
and urinary bladder irradiation volumes may be reduced 
using the scanning technique [31, 32]. Therefore, more 
Table 2. Summary of disease control and survival data.
Outcome Group Number of events (%)
Survival and control rates at 5 years  
(95% CI)
bRFS Low risk 9 (4.2) 97.0 (93.4, 98.6)
Intermediate risk 67 (12.9) 91.0 (88.2, 93.2)
High risk 113 (20.3) 83.2 (79.8, 86.1)
OS Low risk 3 (1.4) 98.4 (95.2, 99.5)
Intermediate risk 22 (4.2) 96.8 (94.9,98.0)
High risk 32 (5.8) 95.2 (93.0,96.7)
CSS Low risk 0 (0.0) 100 (- )
Intermediate risk 1 (0.2) 100 (- )
High risk 3 (0.5) 99.6 (98.5, 99.9)
bRF Low risk 6 (2.8) 98.6 (95.6, 99.5)
Intermediate risk 47 (9.0) 93.9 (91.4, 95.7)
High risk 84 (15.1) 87.4 (84.3, 89.9)
cRF Low risk 1 (0.5) 100 (- )
Intermediate risk 11 (2.1) 98.2 (96.6, 99.1)
High risk 23 (4.1) 95.9 (93.9, 97.3)
CI, confidence interval; bRFS, biochemical relapse- free survival; OS, overall survival; CSS, cause- specific survival; bRF, biochemical relapse- free; cRF, 
clinical relapse- free.
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favorable outcomes than those achieved in the present 
study are expected in the future.
Quality of life evaluations and cost- effectiveness are 
important when comparing radiation therapies for prostate 
cancer, but were not surveyed herein. In the study by 
Sheets et al. [14], no significant differences were observed 
in toxicity or QOL. However, as a limit of the analysis 
from the database, there were miscellaneous doses, mixed 
examples of X- rays combined, and insufficient matching. 
Therefore, the accumulation of more data is necessary. 
Hoppe et al. [15] surveyed QOL evaluations of patients 
who received IMRT and PT using EPIC. No significant 
Table 3. Univariate Cox analysis for disease control and survival.
Outcome Factor N of data
N of events 
(%) Level
Unadjusted HR 
(95% CI) P
P for the 
global test
bRFS NCCN risk group 1291 189 (14.6) Intermediate vs. low 3.23 (1.61, 6.47) <0.001 <0.001
High vs. low 5.39 (2.73, 10.62) <0.001
High vs. intermediate 1.67 (1.23, 2.26) <0.001
Age 1291 189 (14.6) Increase of 10 years 1.28 (1.04, 1.57) 0.021 0.021
Performance status 1291 189 (14.6) 1≤ vs. 0 2.37 (1.59, 3.55) <0.001 <0.001
Operability 1291 189 (14.6) Inoperable vs. operable 1.96 (1.44, 2.67) <0.001 <0.001
T stage 1289 188 (14.6) 2b- 2c vs. 1c- 2a 1.50 (1.06, 2.14) 0.024 <0.001
3a≤ vs. 1c- 2a 2.18 (1.54, 3.10) <0.001
PSA 1289 188 (14.6) 10–20 vs. <10 1.98 (1.42, 2.78) <0.001 <0.001
20< vs. <10 2.34 (1.64, 3.34) <0.001
Gleason score 1288 188 (14.6) 7 vs. 6 2.34 (1.47, 3.73) <0.001 <0.001
8–10 vs. 6 3.78 (2.39, 5.98) <0.001
ADT 1291 189 (14.6) Yes vs. No 1.58 (1.16, 2.15) 0.004 0.004
ADT period 706 122 (17.3) Increase of 10 months 1.00 (0.91, 1.10) 0.94 0.94
ADT period (pattern 
1, month)
1229 180 (14.6) 0<, ≤ 6 vs. 0 1.90 (1.33, 2.70) <0.001 0.005
6<, <12 vs. 0 1.29 (0.74, 2.24) 0.37
12≤ vs. 0 1.33 (0.89, 1.99) 0.16
ADT period (pattern 
2, month)
1229 180 (14.6) 0<, ≤ 12 vs. 0 1.70 (1.21, 2.38) 0.002 0.022
12<, <24 vs. 0 1.27 (0.68, 2.36) 0.45
24≤ vs. 0 1.42 (0.90, 2.22) 0.13
Total dose (GyE)a 1291 189 (14.6) Increase of 10 GyE 0.52 (0.17, 1.59) 0.25 0.25
Higher or lower dose 1291 189 (14.6) 74 GyE < vs. ≤ 74 GyE 0.77 (0.49, 1.23) 0.28 0.28
OS Group 1291 57 (4.4) Intermediate vs. low 3.12 (0.93, 10.42) 0.065 0.045
High vs. low 4.25 (1.30, 13.89) 0.017
High vs. intermediate 1.36 (0.79, 2.35) 0.26
Age 1291 57 (4.4) Increase of 10 years 2.64 (1.77, 3.95) <0.001 <0.001
Performance status 1291 57 (4.4) 1≤ vs. 0 3.62 (1.91, 6.85) <0.001 <0.001
Operability 1291 57 (4.4) Inoperable vs. operable 2.46 (1.43, 4.22) 0.001 0.001
T stage 1289 57 (4.4) 2b- 2c vs. 1c- 2a 1.08 (0.56, 2.10) 0.81 0.48
3a≤ vs. 1c- 2a 1.51 (0.78, 2.92) 0.22
PSA 1289 56 (4.3) 10–20 vs. <10 1.35 (0.72, 2.52) 0.35 0.28
20< vs. <10 1.67 (0.86, 3.22) 0.13
Gleason score 1288 56 (4.3) 7 vs. 6 2.79 (1.22, 6.40) 0.015 0.043
8–10 vs. 6 2.71 (1.15, 6.37) 0.023
ADT 1291 57 (4.4) Yes vs. No 1.90 (1.06, 3.43) 0.032 0.032
ADT period 706 40 (5.7) Increase of 10 months 0.95 (0.80, 1.14) 0.61 0.61
ADT period (pattern 
1, month)
1229 55 (4.5) 0<, ≤ 6 vs. 0 2.41 (1.25, 4.64) 0.009 0.075
6<, <12 vs. 0 1.55 (0.56, 4.27) 0.40
12≤ vs. 0 1.60 (0.76, 3.37) 0.21
ADT period (pattern 
2, month)
1229 55 (4.5) 0<, ≤ 12 vs. 0 2.20 (1.17, 4.11) 0.014 0.094
12<, <24 vs. 0 1.18 (0.34, 4.08) 0.79
24≤ vs. 0 1.73 (0.76, 3.96) 0.19
Total dose (GyE)a 1291 57 (4.4) Increase of 10 GyE 0.39 (0.05, 3.22) 0.39 0.39
Higher or lower dose 1291 57 (4.4) 74 GyE < vs. ≤ 74 GyE 0.63 (0.25, 1.58) 0.33 0.33
N, number; HR, hazard ratio; CI, confidence interval; bRFS, biochemical relapse- free survival; NCCN, National Comprehensive Cancer Network; vs., 
versus; PSA, prostate- specific antigen; ADT, androgen deviation therapy; OS, overall survival.
aThe dose of hypofractionation was converted to conventional dose fractionation using a linear–quadratic model.
The global test is an assessment of whether a factor is significant.
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differences were noted in the total score between the two 
groups; however, rectal urgency (P = 0.02) and frequent 
bowel movements (P = 0.05) were favorable in the PT 
group, and this may have being due to the rectal dose 
being reduced in PT, whereas it was not possible to reduce 
the urethral dose. Based on these findings, PARTIQoL 
(NCT01617161) is being conducted in the United States 
and an interim analysis is scheduled for 2018 [33].
The biggest issue associated with PT is cost. Verma 
et al. conducted a systematic review and showed that 
cost- effectiveness for prostate cancer treated with PT is 
suboptimal [17]. If the cost of PT is sufficiently reduced, 
it may become more widely performed even though 
differences in its effects and adverse events from those 
of IMRT are small. One solution to achieve favorable 
cost- benefit performance while sufficiently utilizing the 
physical advantage of PT may be the introduction of 
hypofractionation. Although the use of a linear–quadratic 
model is controversial for conversion to hypofractiona-
tion [34, 35], similar to radiobiology, hypofractionation 
is theoretically advantageous for prostate cancer and 
also needs to be considered for PT in order to reduce 
the burden on patients. The mean α/β value of prostate 
cancer was previously reported to be approximately 
Table 4. Multivariate Cox analysis for disease control and survival.
Outcome Factor Adjusted HR (95% CI) P
bRFS NCCN risk group, intermediate vs. low 3.24 (1.60, 6.56) 0.001
NCCN risk group, high vs. low 5.04 (2.42, 10.48) <0.001
NCCN risk group, high vs. intermediate 1.55 (1.09, 2.20) 0.014
Age, Increase of 10 years 1.04 (0.84, 1.30) 0.70
Performance status, 1≤ vs. 0 1.87 (1.23, 2.85) 0.003
Operability, inoperable vs. operable 1.42 (1.01, 1.99) 0.045
ADT, Yes vs. No 0.85 (0.59, 1.23) 0.39
OS NCCN risk group, intermediate vs. low 2.57 (0.75, 8.74) 0.13
NCCN risk group, high vs. low 2.58 (0.72, 9.30) 0.15
NCCN risk group, high vs. intermediate 1.01 (0.54, 1.87) 0.99
Age, increase of 10 years 2.07 (1.36, 3.16) <0.001
Performance status, 1≤ vs. 0 2.03 (1.02, 4.03) 0.043
Operability, inoperable vs. operable 1.50 (0.83, 2.72) 0.18
ADT, Yes vs. No 1.07 (0.54, 2.12) 0.85
HR, hazard ratio; CI, confidence interval; bRFS, biochemical relapse- free survival; NCCN, National Comprehensive Cancer Network; vs., versus; ADT, 
androgen deviation therapy; OS, overall survival.
Figure 3. Cumulative incidence rates of the late grade 2 or more severe gastrointestinal toxicity curve (A) and late genitourinary toxicity curve (B).
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Table 5. Univariate Cox analysis for toxicities.
Outcome Factor
N of 
data
N of events 
(%) Level
Unadjusted HR 
(95% CI) P
P for the 
global 
test
GUa NCCN risk group 1291 52 (4.0) Intermediate vs. low 1.39 (0.60, 3.24) 0.44 0.74
High vs. low 1.24 (0.53, 2.90) 0.62
High vs. intermediate 0.89 (0.50, 1.60) 0.69
Age 1291 52 (4.0) Increase of 10 years 1.68 (1.12, 2.50) 0.011 0.011
Performance status 1291 52 (4.0) 1≤ vs. 0 0.78 (0.24, 2.49) 0.67 0.67
Operability 1291 52 (4.0) Inoperable vs. operable 2.13 (1.20, 3.81) 0.010 0.010
T stage 1289 52 (4.0) 2b- 2c vs. 1c- 2a 1.10 (0.55, 2.18) 0.79 0.68
3a≤ vs. 1c- 2a 1.37 (0.67, 2.80) 0.38
PSA 1289 52 (4.0) 10–20 vs. <10 2.06 (1.10,3.83) 0.023 0.043
20< vs. <10 1.97 (0.97, 3.97) 0.060
Gleason score 1288 52 (4.0) 7 vs. 6 1.23 (0.64, 2.37) 0.53 0.49
8–10 vs. 6 0.82 (0.39, 1.75) 0.61
ADT 1291 52 (4.0) Yes vs. No 2.31 (1.21, 4.41) 0.011 0.011
ADT period 706 34 (4.8) Increase of 10 months 1.21 (1.07, 1.37) 0.002 0.002
ADT period (pattern 1, 
month)
1229 180 (14.6) 0<, ≤ 6 vs. 0 0.84 (0.31, 2.23) 0.72 <0.001
6<, <12 vs. 0 2.04 (0.72, 5.78) 0.18
12≤ vs. 0 3.64 (1.81, 7.31) <0.001
ADT period (pattern 2, 
month)
1229 46 (3.7) 0<, ≤ 12 vs. 0 1.31 (0.60, 2.87) 0.50 0.002
12<, <24 vs. 0 2.97 (1.11, 7.90) 0.030
24≤ vs. 0 3.75 (1.76, 8.01) <0.001
Diabetes mellitus 1291 52 (4.0) Yes vs. No 0.17 (0.02, 1.20) 0.076 0.076
Hypertension 1291 52 (4.0) Yes vs. No 0.92 (0.02, 1.20) 0.80 0.80
Anticoagulant therapy 1291 52 (4.0) Yes vs. No 1.16 (0.52, 2.57) 0.72 0.72
Total dose (GyE)b 1291 52 (4.0) Increase of 10 GyE 3.26 (0.64, 16.53) 0.15 0.15
Higher or lower doseb 1291 52 (4.0) 74 GyE < vs. ≤ 74 GyE 2.03 (1.08, 3.81) 0.027 0.027
GIa Group 1291 53 (4.1) Intermediate vs. low 0.97 (0.44, 2.11) 0.93 1.00
High vs. low 0.99 (0.46, 2.14) 0.98
High vs. intermediate 1.02 (0.57, 1.85) 0.94
Age 1291 53 (4.1) Increase of 10 years 1.45 (0.98, 2.14) 0.063 0.063
Performance status 1291 53 (4.1) 1≤ vs. 0 1.35 (0.54, 3.38) 0.53 0.53
Operability 1291 53 (4.1) Inoperable vs. operable 0.88 (0.43, 1.80) 0.72 0.72
T stage 1289 53 (4.1) 2b- 2c vs. 1c- 2a 0.55 (0.25, 1.23) 0.15 0.31
3a≤ vs. 1c- 2a 0.75 (0.34, 1.67) 0.48
PSA 1289 53 (4.1) 10–20 vs. <10 1.07 (0.56, 2.06) 0.83 0.89
20< vs. <10 1.19 (0.58, 2.44) 0.63
Gleason score 1288 53 (4.1) 7 vs. 6 0.90 (0.46, 1.76) 0.76 0.88
8–10 vs. 6 1.06 (0.53, 2.10) 0.87
ADT 1291 53 (4.1) Yes vs. No 0.82 (0.48, 1.40) 0.46 0.46
ADT period 706 26 (3.7) Increase of 10 months 0.90 (0.70, 1.15) 0.40 0.40
ADT period (pattern 1, 
month)
1229 50 (4.1) 0<, ≤ 6 vs. 0 0.83 (0.42, 1.66) 0.60 0.56
6<, <12 vs. 0 1.19 (0.49, 2.91) 0.71
12≤ vs. 0 0.61 (0.27, 1.35) 0.22
ADT period (pattern 2, 
month)
1229 50 (4.1) 0<, ≤ 12 vs. 0 0.89 (0.48, 1.64) 0.71 0.57
12<, <24 vs. 0 0.99 (0.34, 2.86) 0.99
24≤ vs. 0 0.47 (0.16, 1.35) 0.16
Diabetes mellitus 1291 53 (4.1) Yes vs. No 0.70 (0.25, 1.94) 0.50 0.50
Hypertension 1291 53 (4.1) Yes vs. No 1.34 (0.75, 2.41) 0.33 0.33
Anticoagulant therapy 1291 53 (4.1) Yes vs. No 1.36 (0.64, 2.89) 0.42 0.42
Total dose (GyE)b 1291 53 (4.1) Increase of 10 GyE 0.36 (0.04, 2.88) 0.33 0.33
Higher or lower doseb 1291 53 (4.1) 74 GyE < vs. ≤ 74 GyE 0.48 (0.17, 1.33) 0.16 0.16
N, number; HR, hazard ratio; CI, confidence interval; GU, genitourinary; NCCN, National Comprehensive Cancer Network; vs., versus; PSA, prostate- 
specific antigen; ADT, androgen deviation therapy; GI, gastrointestinal.
aGrade 2 or more severe. bThe dose of hypofractionation was converted to conventional dose fractionation using a linear–quadratic model.
The global test is an assessment of whether a factor is significant.
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1.5–3.1 Gy, which is very low [36, 37], and the potential 
doubling time was 30 days or longer, which is very 
long [38]. When dose fractionations of 70 Gy/28 Fr and 
63 Gy/21 Fr were compared with 78 Gy/39 Fr on the 
assumption that the α/β value of prostate cancer is 
1.5 Gy and that of late rectal disorders is 3.0 Gy, 2 Gy- 
converted effects were 80 and 81 Gy, being similar or 
higher, while those of the rectal dose were 77 and 
75.6 Gy, being theoretically reduced. However, the inci-
dence of adverse events induced by X- ray IMRT hypo-
fractionation was unexpectedly high in several studies 
[26, 27]. Therefore, hypofractionated PT may exert 
efficacy by reducing the irradiation volume of the organs 
at risk to less than that in IMRT. A clinical study on 
hypofractionated PT has been initiated, such as that 
reported by Henderson et al. [39].
In conclusion, this retrospective analysis of a multi- 
institutional survey suggested that PT is effective and 
tolerated well for prostate cancer. However, further evi-
dence for the effectiveness of PT for prostate cancer is 
needed. Based on the present results, a multi- institutional 
prospective clinical trial involving all participating Japanese 
PT centers has just been started in order to evaluate the 
efficacy, toxicities, QOL, and cost- effectiveness of PT and 
define its role in the treatment of prostate cancer in Japan 
(UMIN000025453). The data obtained will be compared 
to those from a large cohort registered to the Japanese 
Radiation Oncology Study Group in the future.
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